Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

2 terminated out of 26 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

23%

6 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed with results

Key Signals

3 with results87% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (6)
P 2 (4)
P 3 (3)
P 4 (3)

Trial Status

Completed13
Unknown5
Recruiting3
Withdrawn2
Terminated2
Not Yet Recruiting1

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT04700202Completed

Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

NCT06134492Phase 3Recruiting

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT04153682Not ApplicableCompletedPrimary

Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.

NCT05483309Not ApplicableCompletedPrimary

Feasibility Study of Contemporary Diagnostics for Patients With Suspected Hospital-Acquired Pneumonia.

NCT05733104Recruiting

A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

NCT06168734Phase 3Withdrawn

Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP

NCT04774094Phase 4CompletedPrimary

Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

NCT05785442Phase 2Completed

Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

NCT03496220Not ApplicableCompleted

Effect of Angulus on Patient-elevation Compliance

NCT05979545Phase 4Recruiting

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

NCT05624684Completed

Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.

NCT05663905Phase 4Completed

Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients

NCT05060718CompletedPrimary

HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies

NCT06028217Not Yet RecruitingPrimary

Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment

NCT05914584Phase 2UnknownPrimary

"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

NCT05418517Unknown

Hospital Acquired Pneumonia in Temporary Tracheostomy

NCT04937075CompletedPrimary

Impact of Antimicrobial Stewardship on Outcomes of Patients With Hospital-acquired Pneumonia Due to Gram-negative Bacilli - A Before-after Study

NCT04403971Not ApplicableCompletedPrimary

0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia

NCT04381247Unknown

Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway

NCT03361085Not ApplicableTerminatedPrimary

Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)

Scroll to load more

Research Network

Activity Timeline